Abstract Recently, the number of studies on male breast cancer (MBC) has been increasing. However, as MBC is a rare disease there are difficulties to undertake studies to identify specific MBC subgroups. At present, it is still largely unknown whether BRCA-related breast cancer (BC) in men may display specific characteristics as it is for BRCArelated BC in women. To investigate the clinical-pathologic features of MBC in association with BRCA mutations we established a collaborative Italian Multicenter Study on MBC with the aim to recruit a large series of MBCs. A total of 382 MBCs, including 50 BRCA carriers, were collected from ten Italian Investigation Centres covering the whole country. In MBC patients, BRCA2 mutations were associated with family history of breast/ovarian cancer -012-2062-0 association with personal history of other cancers (OR 11.42,) and high tumor grade (OR 4.93,) and inverse association with PR? status (OR 0.19,). Based on immunohistochemical (IHC) profile, four molecular subtypes of MBC were identified. Luminal A was the most common subtype (67.7 %), luminal B was observed in 26.5 % of the cases and HER2 positive and triple negative were represented by 2.1 % and 3.7 % of tumors, respectively. Intriguingly, we found that both luminal B and HER2 positive subtypes were associated with high tumor grade (p = 0.003 and 0.006, respectively) and with BRCA2 mutations (p = 0.016 and 0.001, respectively). In conclusion, our findings indicate that BRCA2-related MBCs represent a subgroup of tumors with a peculiar phenotype characterized by aggressive behavior. The identification of a BRCA2-associated phenotype might define a subset of MBC patients eligible for personalized clinical management.
association with personal history of other cancers (OR 11.42, 95 % CI 1.79-73.08) and high tumor grade (OR 4.93, 95 % CI 1.02-23.88) and inverse association with PR? status (OR 0.19, 95 % CI 0.04-0.92). Based on immunohistochemical (IHC) profile, four molecular subtypes of MBC were identified. Luminal A was the most common subtype (67.7 %), luminal B was observed in 26.5 % of the cases and HER2 positive and triple negative were represented by 2.1 % and 3.7 % of tumors, respectively. Intriguingly, we found that both luminal B and HER2 positive subtypes were associated with high tumor grade (p = 0.003 and 0.006, respectively) and with BRCA2 mutations (p = 0.016 and 0.001, respectively). In conclusion, our findings indicate that BRCA2-related MBCs represent a subgroup of tumors with a peculiar phenotype characterized by aggressive behavior. The identification of a BRCA2-associated phenotype might define a subset of MBC patients eligible for personalized clinical management.
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Introduction
Breast cancer (BC) in men is a rare disease accounting for \1 % of all cancers in men and \1 % of all BCs. However, recent epidemiologic studies suggest that the incidence of male breast cancer (MBC) is increasing by 1.1 % yearly [1, 2] .
Compared with female BC (FBC), MBC occurs later in life, with higher stage and lower grade and more often displays positive estrogen and progesterone receptors (ER and PR) status [3, 4] .
MBC is likely to be caused by the concurrent effects of different risk factors, including hormonal, environmental and particularly genetic risk factors, such as mutations in BRCA1 and, mainly, BRCA2 genes [5, 6] .
It is now well established that in women BRCA-associated BCs tend to manifest specific genotype-phenotype correlations [7] . In particular, BRCA1-related BCs have distinct morphology and show a triple negative (ER-, PR-, HER2-) phenotype [8] . By contrast, BRCA2-related BCs are a heterogeneous group not fully characterized [9] [10] [11] . The current knowledge on phenotypic characteristics of BRCA-associated MBCs is thus far quite limited [5] .
Furthermore, while it is generally accepted that FBC is a heterogeneous disease, whether MBC can be classified into comprehensive molecular subtypes remains to be elucidated. Indeed, the classification into molecular subtypes based on immuno-phenotypic features, as proposed for FBC, is still controversial in MBC. It has been reported that the luminal A (ER? and/or PR?, HER2-) and luminal B (ER? and/or PR?, HER2?) are the most common subtypes in MBC, whereas triple negative (ER-, PR-, HER2-) and HER2 positive (HER2?/ER-, PR-) are very rare [12] [13] [14] .
Overall, knowledge about specific biological and molecular characteristics of MBC is still largely unknown.
Given the paucity of data and the rarity of the disease, an effort in establishing collaborative studies is fundamental to obtain large series of MBCs with detailed epidemiological and molecular data. Therefore, we established the first Italian Multicenter Study on MBC to recruit a large series of cases from the whole Country, with the aim to better examine the clinical-pathologic features of MBC cases in association with BRCA mutational status and to identify molecular subtypes of MBC that could provide useful information for understanding the pathogenesis of this disease and, eventually, for clinical management of MBC patients. Clinicopathological data were collected through several mechanisms, including medical records and pathology reports. For some centers, tumor pathology was independently reviewed by study pathologists. Four cases were excluded from the current analysis because of missing age at diagnosis. Then, this study is focused on 378 subjects with 394 BCs (including 16 subjects with contralateral BC).
Materials and methods

Study population
The study was approved by the local ethical committee. Written informed consent was obtained from all study subjects.
Molecular characterization
BRCA1 and BRCA2 mutation analysis was performed in the frame of genetic counselling programs at the center of origin for all MBC cases. BRCA1/2 mutations were classified according to their potential functional effect and only the pathogenic loss-of-function mutations were considered in the analysis.
ER, PR, Ki-67, and HER2 status of breast tumors were extracted from medical, pathology, or tumor registry records or obtained from IHC analysis of sections from formalin-fixed, paraffin-embedded primary mammary tumor blocks. HER2 status was assessed by FISH analysis in ambiguous cases (IHC score = 2?). Cut-off values were as previously reported [15, 16] .
Based on IHC profiles, MBCs were classified according to the following molecular subtypes: luminal A (ER? and/ or PR?, HER2-), luminal B (ER? and/or PR?, HER2?), HER2 positive (ER-and PR-, HER2?), and triple negative (ER-, PR-, HER2-).
Statistical analysis
The association between selected clinical-pathologic and molecular features and specific groups of MBCs was assessed by using Fisher's exact test or v 2 for trend as appropriate (two sided). A multivariate logistic model including selected parameters (cancer personal history, 1st degree FH of breast/ovarian cancer, contralateral cancer, grading, stage, PR and HER2 status) was used to evaluate the association between the characteristics included in the model and BRCA2 mutations. p values B0.05 were considered statistically significant.
Results
Clinical-pathologic characteristics of MBC cases
Clinical characteristics of 378 MBC patients and pathologic features of the 394 breast tumors from the 378 MBC patients included in this study are reported in Table 1 .
Age at first MBC diagnosis ranged between 22 and 90 years, with a mean age of 60.9 years (SD: 11.9). Six out of 139 cases (4.3 %) with a positive FH of breast or ovarian cancer in first-degree relatives had a first-degree male The 46 BRCA2 mutation positive MBC patients showed a mean age at diagnosis of 58.9 years (SD: 11.7), and 31 (67.4 %) had a positive first-degree FH of breast and/or ovarian cancer (Table 2 ). 12 cases (26.1 %) had a personal history of other cancers, mainly prostate cancer (58 %) and 7 patients (15.2 %) had a diagnosis of contralateral BC. BRCA2-related MBCs were mostly invasive ductal carcinomas (88.3 %), G3 (54.8 %), stages I-II (62.5 %), ER? (89.7 %), PR? (67.9 %), HER2? (63.2 %), lymph-node positive (56.7 %), and Ki-67 high (56.2 %) tumors. As shown in Table 2 
Molecular subtypes of MBC cases
The classification into molecular subtypes and their characterization was available for a subset of 189 tumors, 
Discussion
In this study, a large series of MBC cases, derived from the collaborative Italian Multicenter Study on MBC, was analyzed to investigate the clinical-pathologic features of MBC in association with BRCA mutations and to characterize immuno-phenotypic subtypes of MBC. A total of 382 MBC cases, including 50 BRCA1/2 mutation carriers, and their clinical-pathologic characteristics, were collected from ten Italian Investigation Centres in different areas of the Country, from Northern to Southern Italy. Despite differences in study populations and method of collecting data, the distributions of clinical-pathologic variables considered in this study (i.e., ER, PR, and HER2) were generally consistent across different Investigation Centers.
To the best of our knowledge this series represents the largest MBC series ever assembled in a single country for which BRCA1 and BRCA2 mutational status and extensive clinical-pathologic data are available.
As expected, BRCA2 mutations were found to be more frequent than BRCA1 mutations (12.2 vs 1.1 %). It is noteworthy that two of the four BRCA1 mutation carriers found in our series harbor the same mutation that was previously identified as a founder mutation in Central Italy [17] . Compared with previous studies, in our series age at diagnosis was lower and the percentage of cases with a positive first-degree FH was higher [18] [19] [20] [21] . This could reflect the presence of MBC patients enrolled in a context of genetic counselling programs, which are more frequently characterized by familial cancer and younger age at diagnosis. On the other hand, the pathologic characteristics of male breast tumors, including histology, stage, grade, and hormone receptor expression were consistent with former studies (Table 1 in Supplementary material). Thus, our series can be regarded as representative. Overall, MBCs present as invasive ductal carcinomas, G2 and stages I-II disease and express ER and PR.
Taken advantage of our large BRCA1/2 characterized MBC series we investigated whether specific BRCA-associated phenotypes could be identified in MBC. We found that all four BRCA1-associated MBCs were HER2-with one case disclosing a triple negative phenotype. The majority of BRCA1-related MBCs were G3 tumors and show high proliferative activity. Although based on a few cases, our results may suggest that BRCA1-related BCs in men represent a rare event characterized by a phenotype similar to that observed in women. On the other hand, BRCA2-associated MBCs display a characteristic BRCA2-associated BC phenotype not identified in women [11] . In particular, BRCA2-associated MBCs present with high tumor grade, the absence of PR expression, and HER2 positive status. Indeed, we have previously reported statistically significant associations between BRCA2 tumors and high tumor grade, PR-and HER2? status in a series of 108 MBCs [5] . In this study, these associations also emerged either including or excluding (data not shown) the previous analyzed series thus confirming on a large and independent series our earlier results.
Here, we also observed that germ-line BRCA2 mutations are associated with positive personal history of other cancers and contralateral BC in MBC patients. These findings are particularly relevant for a personalized clinical management of MBC patients. In fact, they confirm the needing of an intensive cancer surveillance, particularly prostate cancer surveillance [22] , after first diagnosis of BC and might raise the question of performing a bilateral prophylactic mastectomy at the surgery time in BRCA2-associated MBC patients. Furthermore it is noteworthy that, in a multivariate logistic analysis, cancer personal history, high tumor grade, and PR-status emerged to be all statistically associated with BRCA2 mutations independently. Taking into consideration that the majority of MBCs are PR?, the finding that PR-MBCs are associated with BRCA2 mutations may have an important predictive value, thus improving the earlier detection of BRCA2 mutation carriers.
Based on IHC profile, in this study we also characterized molecular subtypes of MBC. Luminal A resulted the most common subtype, followed by luminal B, triple negative, and HER2 positive subtypes. Overall, our results are consistent with a recent published article showing that luminal A and, to a lesser extent, luminal B types represent the vast majority of BC in men whereas triple negative and HER2 positive subtypes are rare [13] . Intriguingly, we found that both HER2 positive and luminal B subtypes were associated with BRCA2 mutations. Notably, all previous studies were performed in MBCs not characterized for BRCA2 mutations, and, based on BRCA2 mutation frequency and on the number of cases analyzed, BRCA2-related MBCs were likely rare, if any, in the published series. This could probably explain why HER2 positive and luminal B subtypes have been, thus far, infrequently reported in MBC [12] [13] [14] . We also found a statistically significant association between both HER2 positive and luminal B subtypes with high tumor grade. Taken together, these data suggest that in men luminal B and HER2 positive BC subtypes are associated with characteristic unfavorable prognostic factors, such as high grade, and are BRCA2-related BCs.
Although we had a large sample size, missing data for molecular markers may have limited the power of our findings. Thus, a further effort in collecting more MBC cases together with their epidemiological and molecular features is currently in progress.
In conclusion, our findings indicate that BRCA2-related MBCs represent a subgroup of tumors with a peculiar phenotype characterized by aggressive behavior. The identification of a BRCA2-associated phenotype might define a subset of MBC patients eligible for personalized clinical management and for targeted therapy. Overall, results from this study may be helpful in improving the understandings and the management of this rare disease and deserve to be confirmed in large international collaborative studies.
